

Neurotech to Present at NWR Virtual Healthcare Conference

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces an upcoming presentation by Dr Thomas Duthy, Executive Director at the NWR Virtual Healthcare Conference on 21 and 22 March 2023.

Dr Duthy will be presenting at 8.30am AEDT on Wednesday 22 March 2023.

Investors who wish to register for the presentation can do so at the following link: https://us02web.zoom.us/webinar/register/WN_cnfTyrHSTutZpujNbSMYQ

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels. Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au.

For more information please visit: <https://nwrcommunications.com/healthconf>

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Investors:

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

Media:

Lisa Blake
LBPR
lisa@lbpr.com.au
+61 (0) 429 976 718

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days and 20 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech plans to conduct additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with cerebral palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.